EU/3/07/435

Table of contents

About

On 20 February 2007, orphan designation (EU/3/07/435) was granted by the European Commission to Pharming Group N.V., Netherlands, for recombinant human C1-inhibitor for the prevention of delayed graft function in organ transplant.

Key facts

Active substance
Recombinant human C1-inhibitor
Disease / condition
Prevention of delayed graft function after solid organ transplantation
Date of first decision
20/02/2007
Outcome
Positive
EU designation number
EU/3/07/435

Sponsor's contact details

Pharming Group N.V.
Darwinweg 24
2333 CR Leiden
The Netherlands
Telephone: +31 71 52 47 400
Telefax: +31 71 52 47 445
E-mail: info@pharming.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating